Radu Neamu, MD
Pulmonary Disease · Lincoln, NENPI 1083895577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in NE, where the typical reported total is $2,614.
Across 31 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$172
- Abiomed$100
- Sanofi$99
- Inspire Medical Systems, Inc.$87
- Insmed, Inc.$59
- Resmed Corp$48
- plus $156 from 7 others
Across 154 payments — averaging $3040.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$337K
- AstraZeneca$38K
- Sanofi US Services Inc.$32K
- Amgen$32K
- Insmed, Inc.$19K
- Chiesi USA, Inc.$12K
What the payments were for
- Food & beverage$70498%
- Education$172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 10 | $172 |
| Abiomed | 2 | $100 |
| Sanofi | 4 | $99 |
| Inspire Medical Systems, Inc. | 1 | $87 |
| Insmed, Inc. | 3 | $59 |
| Resmed Corp | 1 | $48 |
| Amgen | 2 | $34 |
| Grifols USA, LLC | 2 | $33 |
| Novartis | 2 | $27 |
| AstraZeneca | 1 | $18 |
| United Therapeutics Corporation | 1 | $15 |
| Pfizer | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$722 in reported general payments places this provider in the 30th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 32 | $352,132 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 269 | $206,935 |
| Spiriva RespimatTiotropium Bromide | 170 | $113,469 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 168 | $108,778 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $43,031 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 47 | $36,515 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 51 | $34,147 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 65 | $30,417 |
| SymbicortBudesonide/Formoterol Fumarate | 86 | $25,719 |
| Pirfenidone | 14 | $15,488 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $14,338 |
| DuleraMometasone/Formoterol | 34 | $13,113 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $11,309 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $9,322 |
| EliquisApixaban | 16 | $9,213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $14 | $536,263300 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $18 | $134,497254 claims |
| PfizerEliquis | $15 | $9,21316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Lincoln
- Ryan MartinLincoln$600K
- Douglas FiedlerLincoln$23K
- Kevin ReichmuthLincoln$22K
- Harvey HopkinsLincoln$18K
- William JohnsonLincoln$18K
- Matthew MaslonkaLincoln$14K
- Jakeb RiggleLincoln$13K
- Jonathan SpencerLincoln$9K
- Louis VioliLincoln$6K
- Jeffrey JarrettLincoln$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.